Sulfasalazine treatment and lymphocyte function in patients with rheumatoid arthritis.
Sulfasalazine is now an established 2nd line agent in the treatment of rheumatoid arthritis (RA) but its mode of action is unknown. Two separate studies have investigated the possibility that it works in RA by influencing lymphocyte function. After 12 weeks of treatment with sulfasalazine, elevated levels of circulating activated lymphocytes and abnormal ex vivo mitogen response to concanavalin A (Con-A) in 11 patients with RA reverted to normal. An in vitro study investigated the effect of sulfasalazine and its metabolites on mitogen response by healthy and RA peripheral blood mononuclear cells (PBMC). Sulfapyridine (SP) and 5-hydroxy SP suppressed the response of RA PBMC to Con-A. Sulfasalazine, SP and N-acetyl SP suppressed the response of healthy PBMC to pokeweed mitogen. 5-aminosalicylic acid also affected mitogen response and cell viability, which may be relevant to actions of this metabolite within the gut.
D000636:Aminosalicylic Acids / Q000494:pharmacology; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D002470:Cell Survival; D005260:Female; D006801:Humans; D037102:Lectins; D007958:Leukocyte Count; D007963:Leukocytes, Mononuclear / Q000378:metabolism / Q000473:pathology; D008214:Lymphocytes / Q000502:physiology*; D008297:Male; D019804:Mesalamine; D013427:Sulfapyridine / Q000031:analogs & derivatives / Q000494:pharmacology; D012460:Sulfasalazine / Q000627:therapeutic use*; D013936:Thymidine / Q000378:metabolism
D000636:Aminosalicylic Acids; D037102:Lectins; C005377:N-acetylsulfapyridine; D012460:Sulfasalazine; D019804:Mesalamine; D013936:Thymidine; D013427:Sulfapyridine